BTIG Rates Kymera Therapeutics (KYMR) buy, $134 Price Target
BTIG continues to see potential in Kymera Therapeutics with a $134 price target, a 23.94% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Kymera Therapeutics, Inc. ($KYMR) "buy" with a $134 price target on June 25, 2026.
Since the rating, $KYMR is down 2.5% after 1 week, down 5.5% after 1 month and down 10.0% to date (from the $116.46 close on Jun 25, 2026).
KYMR
Kymera Therapeutics, Inc.
Key Points
- BTIG reiterated its buy rating for Kymera Therapeutics, Inc. (KYMR) with a price target of $134 on June 25, 2026.
- BTIG's $134 price target implies 23.94% upside from Kymera Therapeutics, Inc.'s ($KYMR) current $108.12 share price.
- On Thursday, shares of Kymera Therapeutics traded near $99.87, with a market cap of approximately $8.18 billion.
- Kymera Therapeutics saw insider sales by key executives and continued strong institutional interest, with significant holdings by T. Rowe Price and others.
Get $KYMR trade alerts by text
We text you when insiders, Congress or big funds trade $KYMR. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Kymera Therapeutics, Inc. alert may contain errors. Disclosures
BTIG reiterated its buy rating for Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 25, 2026, maintaining a price target of $134. This reflects continued confidence in the biotechnology company's prospects.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Kymera Therapeutics, Inc. Stock Down 8.2%
Shares of NasdaqGM:KYMR traded near $99.87 on Thursday. Kymera Therapeutics has a market cap of approximately $8.18 billion. The company currently has no meaningful P/E ratio as it is not profitable, with a beta of 2.027, indicating higher volatility compared to the market. The stock has seen a 52-week low of $36.65 and a high of $105.00. It has a 50-day moving average of $83.06 and a 200-day moving average of $73.55.
$KYMR price target
Kymera Therapeutics, Inc. daily closes and this analyst's $134 target. Not advice.
Insider Buying and Selling at Kymera Therapeutics, Inc.
Recent insider activity at Kymera Therapeutics included several sales and one purchase on June 22, 2026. Chief Business Officer Noah Goodman sold 2,500 shares at $99.00, while Bruce Booth executed planned sales totaling over 278,000 shares at various prices. Goodman also bought 2,500 shares at $21.05, showcasing mixed insider sentiment.
Analysts Set New Price Targets
On June 25, 2026, BTIG reiterated its buy rating for Kymera Therapeutics with a $134 price target. Previously, Canaccord Genuity initiated coverage with a buy rating and a $106 target on May 6, 2026. Jefferies assumed a buy rating with a $110 target on March 16, 2026. The consensus among analysts is a strong buy, with a mean target price of $119.19 based on 21 opinions.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing small molecule drugs that target and degrade disease-causing proteins. The company is working on several treatments, including KT-621 for atopic dermatitis and other conditions, KT-579 for autoimmune diseases, and KT-485/SAR447971 for inflammatory diseases. Kymera also collaborates with Sanofi to develop certain drug candidates.
Bottom Line
BTIG's reiterated buy rating and $134 target for Kymera Therapeutics highlight ongoing confidence in the company's potential. Investors should note that this analysis is backward-looking, based on available data and current market conditions. As always, it's essential to conduct thorough research before making any investment decisions.
Related Filing Alerts
Source: BTIG's rating change on $KYMR (Jun 25, 2026). Written by software, not financial advice. How we make alerts